These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 2506556

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM, van der Meijden AP, Schreinemachers LM, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg EJ.
    Prog Clin Biol Res; 1988 Feb; 269():511-24. PubMed ID: 3134662
    [No Abstract] [Full Text] [Related]

  • 5. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
    Witjes WP, van der Meijden PM, Roos EP, Witjes JA, Steerenberg PA, Doesburg W, Debruyne FM.
    Prog Clin Biol Res; 1992 Feb; 378():59-67. PubMed ID: 1301587
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH, Bouffioux C, Sylvester R, de Pauw M.
    Prog Clin Biol Res; 1988 Feb; 269():525-37. PubMed ID: 3134663
    [No Abstract] [Full Text] [Related]

  • 8. Intravesical chemotherapy.
    Prout GR.
    Prog Clin Biol Res; 1984 Feb; 162B():125-50. PubMed ID: 6438639
    [No Abstract] [Full Text] [Related]

  • 9. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.
    DeBruyne FM, van der Meijden AP, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg JJ.
    Urology; 1988 Mar; 31(3 Suppl):20-5. PubMed ID: 3279698
    [Abstract] [Full Text] [Related]

  • 10. BCG in the management of superficial bladder cancer.
    Guinan P, Richardson C, Hanna M, Rubenstein M.
    Prog Clin Biol Res; 1989 Mar; 303():447-53. PubMed ID: 2675002
    [Abstract] [Full Text] [Related]

  • 11. Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG.
    Soloway MS.
    Prog Clin Biol Res; 1990 Mar; 350():71-9. PubMed ID: 2117289
    [Abstract] [Full Text] [Related]

  • 12. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP, Hall RR, Macaluso MP, Pawinsky A, Sylvester R, Van Glabbeke M.
    Eur Urol; 1996 Mar; 29(2):199-203. PubMed ID: 8647147
    [Abstract] [Full Text] [Related]

  • 13. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
    Steg A, Belas M, Leleu C, Boccon-Gibod L.
    Prog Clin Biol Res; 1989 Mar; 303():375-81. PubMed ID: 2780654
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
    Jauhiainen K, Rintala E, Kaasinen E, Ruutu M, Alfthan O.
    Arch Esp Urol; 1990 Mar; 43 Suppl 2():159-64. PubMed ID: 2129004
    [Abstract] [Full Text] [Related]

  • 15. Treatment of superficial carcinoma of the bladder.
    Paulson DF.
    Prog Clin Biol Res; 1984 Mar; 162B():193-209. PubMed ID: 6209720
    [No Abstract] [Full Text] [Related]

  • 16. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
    Aso Y, Akaza H, Kameyama S, Niijima T.
    Prog Clin Biol Res; 1989 Mar; 303():383-91. PubMed ID: 2675000
    [No Abstract] [Full Text] [Related]

  • 17. [Intravesical instillation in the treatment of superficial tumors of the bladder].
    Chopin DK.
    Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
    [Abstract] [Full Text] [Related]

  • 18. Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
    Prout GR, Kopp J.
    Prog Clin Biol Res; 1984 Apr; 162B():397-427. PubMed ID: 6438644
    [No Abstract] [Full Text] [Related]

  • 19. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ, Shen ZJ, Lu J, Jin XD, Chen J, Shi SF.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 15; 43(22):1457-60. PubMed ID: 16318813
    [Abstract] [Full Text] [Related]

  • 20. Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
    Böhle A, Busemann E, Gerdes J, Ulmer AJ, Flad HD, Jocham D.
    Dev Biol Stand; 1992 Nov 15; 77():199-209. PubMed ID: 1426663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.